ABOUT: GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations.
![](https://wallstreetanalyzer.com/wp-content/uploads/2023/01/Unknown.png)
![](https://wallstreetanalyzer.com/wp-content/uploads/2023/01/Unknown.jpeg)
THIS INTERVIEW HAS EXPIRED